Regeneron Pharmaceuticals News

Form 144 | Regeneron Pharmaceuticals(REGN.US) Director Proposes to Sell 266.72K in Common Stocks

SEC FILLINGS DISCLOSED/ May 1, $Regeneron Pharmaceuticals(REGN.US)$ Director Arthur F. Ryan intends to sell 300 shares of its common stock on May 1, with a total market value of approximately $266.72K

moomoo News17:38 ET

Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 222.35K in Common Stocks

SEC FILLINGS DISCLOSED/ May 1, $Regeneron Pharmaceuticals(REGN.US)$ Officer MARION E MCCOURT intends to sell 250 shares of its common stock on May 1, with a total market value of approximately $222.35

moomoo News17:08 ET

Regeneron Pharmaceuticals(REGN.US) Officer Sells US$15.16 Million in Common Stock

$Regeneron Pharmaceuticals(REGN.US)$ Officer YANCOPOULOS GEORGE sold 16,848 shares of common stock on Jan 2, 2024 at an average price of $900 for a total value of $15.16 million.Source: Announcement(o

moomoo News16:46 ET

Adverum Biotechnologies a New Buy at H.C. Wainwright on Wet AMD Gene Therapy

Seeking Alpha13:18 ET

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaApr 30 13:35 ET

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends

Benzinga's options scanner has just identified more than 16 option transactions on Regeneron Pharmaceuticals (NASDAQ:REGN), with a cumulative value of $427,360. Concurrently, our algorithms picked up

BenzingaApr 30 10:31 ET

Here's Why Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe

Simply Wall StApr 30 07:44 ET

Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround

Yahoo FinanceApr 29 09:35 ET

Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

Yahoo FinanceApr 29 09:16 ET

Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD (aflibercept) Injection

BenzingaApr 29 07:02 ET

Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says

Regeneron Pharmaceuticals (REGN) is expected to grapple with Q1 seasonality when reporting March quarter results early next month, despite the ongoing Eylea HD launch, Oppenheimer said in a note Thurs

MT NewswiresApr 26 12:24 ET

Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125

Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,189, according to analysts polled by Capital IQ. Price: 885.00, Change: -5.68, Percent Ch

MT NewswiresApr 26 08:24 ET

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting dos

BenzingaApr 25 13:58 ET

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ

By David Wainer Bristol-Myers Squibbs market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnin

WSJApr 25 11:15 ET

Regeneron (REGN) Reports Next Week: What You Should Expect

Yahoo FinanceApr 25 10:02 ET

UPDATE 1-AbbVie's Skin Disease Drug Found to Be More Effective Than Regeneron's Dupixent in Study

Yahoo FinanceApr 25 08:44 ET

Express News | Regeneron Pharmaceuticals Inc - Mammoth Eligible to Receive Royalty Rates Ranging From Single Digits to Mid-Teens on Future Net Sales of Products

ReutersApr 25 07:01 ET

Express News | Regeneron Pharmaceuticals Inc - Mammoth Is Eligible to Receive up to $370 Mln per Target in Development, Regulatory and Commercial Milestone Payments

ReutersApr 25 07:00 ET

Express News | Regeneron Pharmaceuticals Inc - Mammoth to Receive $100 Mln Total Upfront Payment and Equity Investment From Regeneron at Signing

ReutersApr 25 07:00 ET

Express News | Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

ReutersApr 25 07:00 ET